Nienke's portfolio encompasses a diverse range of biological subject matter including: personalised medicine, biomarkers, biosimilars, antibodies, immunology, therapeutics, cell biology, biotechnology, enzymology, diagnostics and biopharmaceuticals. She handles all patent related matters including: preparing patent applications, prosecuting patent applications before the EPO and UKIPO, managing worldwide patent prosecution, strategic reviews, due diligence, and validity opinions.
Nienke has considerable experience working with universities and spin-out companies and can bring a depth of commercially relevant advice from her experience in working for a start-up biotech company prior to entering the profession. Nienke also works with SMEs and large multinational companies. Her pragmatic advice is appropriately tailored to her client's individual needs.
Nienke has represented clients before the Oppositions Division of the EPO and has a particular interest in opposition matters. Her ability to quickly assimilate and utilise scientific literature to the benefit of her clients is a key strength during oral proceedings before both the Opposition Division and the Boards of Appeal of the EPO.
Nienke qualified as a Patent Attorney in 2012 and was awarded the Strode Prize for obtaining the highest mark in the UK finals law exam, P2. She also holds a Post-Graduate Certificate in Intellectual Property Law from the Queen Mary, University of London, obtained with distinction. She obtained her PhD from the University of Cambridge in Infection and Immunity and graduated with a First Class Honours degree in Biological Sciences (Genetics) from the University of Leicester with the highest mark in her year.
Biological Sciences (genetics)
Infection and Immunity
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
HGF in Europe and Knobbe Martens in the US are holding a joint webinar on 9th June. In this webinar we will explore considerations for implementing an effective strategy to …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.